Latest News

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025...

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Fina

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class...

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Pote

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Unins...

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episo...

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic M

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva to Present at the Jefferies London Healthcare Conference

Teva to Present at the Jefferies London Healthcare Conference

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance a...

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and In

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Reveal...

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing D

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demon...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrat

Teva Statement on European Commission Decision; Company to Appeal

Teva Statement on European Commission Decision; Company to Appeal

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-ae...

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn),

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candida...

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide ac...

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6,

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitat...

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating M

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘...

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizop...

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophreni

Teva to Present at the Bank of America 2024 Global Healthcare Conference

Teva to Present at the Bank of America 2024 Global Healthcare Conference

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Teva to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Re...

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflam...

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammator

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in ...

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Child

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 3...

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 20

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Compa...

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United...

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United Stat

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Re...

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a On...

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pil

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749...

Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (ola

Teva to Present at the 2024 Bank of America Healthcare Conference

Teva to Present at the 2024 Bank of America Healthcare Conference

Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentratio...

U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Cit

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara®...

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ust

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and P...

Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patien

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Resul...

Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results fr

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, ...

Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Pat...

New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of D...

Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-A

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interch...

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangea

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574)...

Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Anti

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Reports Growth in Fourth Quarter and Full Year 2023

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy

Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy